At first glance, it looks like the cover of a design magazine, but it’s actually the technology supplement published by The Economist in March. Titled ‘The Age of CRISPR,’ it features eight articles exploring the most cutting-edge areas of genome editing—gene therapies, xenotransplantation, epigenetic editing, gene drives, gene-edited plants, and much more. It doesn’t shy away from the challenges, from companies struggling to stay afloat to regulatory hurdles. But the tone is measured: the era of sensationalism is over, yet CRISPR is here to stay.